Gimmy to List on Innovation Board in May, Optimizing Product Portfolio for Growth and Profit
NQ Score
100/100
AI Summary (NQ-processed)
Gimmy Biological Technology, a major gene sequencing company, is set to list on the Innovation Board in early May, with an initial offering price of NT$25 per share. General Manager Chiang Chun-chi stated that the company will optimize its product portfolio, increase the proportion of high-margin diagnostic products, and expand into the Asia-Pacific market. Gimmy aims for balanced growth and profitability, leveraging its DNA sequencing technology and multi-omics laboratories.
AI analysis data is not yet available.